Ajanta Pharma Limited

NSEI:AJANTPHARM 株式レポート

時価総額：₹323.0b

Ajanta Pharma 配当と自社株買い

配当金 基準チェック /56

Ajanta Pharma配当を支払う会社であり、現在の利回りは2.15%で、収益によって十分にカバーされています。

主要情報

2.2%

配当利回り

1.1%

バイバック利回り

総株主利回り3.2%
将来の配当利回り1.5%
配当成長22.4%
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向39%

最近の配当と自社株買いの更新

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Oct 31
Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Recent updates

If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

Mar 29
If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Feb 20
What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 02
Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Dec 15
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
author-image

Branded Generics Growth And Global Expansion Will Accelerate Earnings And Market Share

Dec 14 Ajanta Pharma's strong performance in Branded Generics and effective cash management strategy indicate robust future revenue and margin improvements.

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Sep 10
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Aug 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04
Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

Aug 01
Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Jun 01
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

May 05
Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

Apr 05
Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Feb 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Dec 23
Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Aug 26
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Feb 07
These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Oct 24
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Aug 25
Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

Jul 19
Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Apr 28
A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Mar 14
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Feb 06
I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Dec 13
Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Oct 31
Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Sep 22
Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Sep 08
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Aug 26
Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Jul 07
Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Jun 14
Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

May 15
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 10
Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 11
Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Feb 24
Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

決済の安定と成長

配当データの取得

安定した配当: AJANTPHARMの配当金支払いは、過去10年間 変動性 が高かった。

増加する配当: AJANTPHARMの配当金は過去10年間にわたって増加しています。

配当利回り対市場

Ajanta Pharma 配当利回り対市場
AJANTPHARM 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (AJANTPHARM)2.2%
市場下位25% (IN)0.3%
市場トップ25% (IN)1.3%
業界平均 (Pharmaceuticals)0.8%
アナリスト予想 (AJANTPHARM) (最長3年)1.5%

注目すべき配当: AJANTPHARMの配当金 ( 2.15% ) はIndian市場の配当金支払者の下位 25% ( 0.28% ) よりも高くなっています。

高配当: AJANTPHARMの配当金 ( 2.15% ) はIndian市場 ( 1.31% ) の配当支払者の中で上位 25% に入っています。

株主への利益配当

収益カバレッジ: AJANTPHARMの 配当性向 ( 39.1% ) はかなり低いため、配当金の支払いは利益によって十分にカバーされます。

株主配当金

キャッシュフローカバレッジ: 現在の現金配当性向（ 83.3% ）では、 AJANTPHARMの配当金はキャッシュフローによって賄われています。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2025/05/15 11:27
終値2025/05/15 00:00
収益2025/03/31
年間収益2025/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Ajanta Pharma Limited 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25

アナリスト機関
Rashmi Sancheti ShettyAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
null nullAsian Markets Securities Private Limited